NewsRx

Search our medical news database

Breast Cancer

Positive data reported on phase II breast tumor cell proliferation study

Published in Women's Health Weekly, January 8th, 2004

Ascend Therapeutics, Inc., announced that it presented data from a phase II dose-escalating study comparing the antiproliferative effect of the company's percutaneous TamoGel (4-Hydroxytamoxifen gel) to oral tamoxifen on malignant breast cancer.

The data was presented at the 26th Annual San Antonio Breast Cancer Symposium held December 3-6, 2003, in San Antonio, Texas.

Data from the study concluded that TamoGel has a local impact on tumor proliferation with much lower systemic exposure than tamoxifen, and that TamoGel can be tested in future prospective trials of chemoprevention or ductal carcinoma in situ (DCIS) adjuvant therapy.

...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook